A Study of MAX-40279combined With KN046 in Patients With Advanced / Metastatic Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Advanced / Metastatic Solid Tumors
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Maxinovel Pty., Ltd.
- Target Recruit Count
- 108
- Registration Number
- NCT05425602
A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2022-06-02
- Lead Sponsor
- Maxinovel Pty., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05395780
- Locations
- 🇨🇳
Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jingsu, China
A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors
Phase 1
- Conditions
- Solid Tumor
- Interventions
- Drug: "MAX-40279-01" and "Toripalimab"
- First Posted Date
- 2022-05-11
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Maxinovel Pty., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT05369286
- Locations
- 🇨🇳
Institute of The Sixth Affiliated Hospital Sun Yat-sen University, Guangzhou, Guangdong, China
A Study to Evaluate the Safety of MAX-40070 in Healthy Subjects
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- Maxinovel Pty., Ltd.
- Target Recruit Count
- 78
- Registration Number
- NCT05196711
MAX-10181 in Patients With Advanced Solid Tumor
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- Maxinovel Pty., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT05196360
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China
A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer
- First Posted Date
- 2021-11-22
- Last Posted Date
- 2021-12-06
- Lead Sponsor
- Maxinovel Pty., Ltd.
- Target Recruit Count
- 130
- Registration Number
- NCT05130021
- Locations
- 🇨🇳
The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Phase 1
- Conditions
- LeukemiaRelapsed/Refractory Acute Myeloid LeukemiaMyelodysplastic SyndromeAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2021-10-01
- Lead Sponsor
- Maxinovel Pty., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT05061147
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)
- First Posted Date
- 2019-12-05
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- Maxinovel Pty., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT04187495
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China
MAX-40279-01 in Patients With Advanced Solid Tumors
- First Posted Date
- 2019-12-03
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- Maxinovel Pty., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT04183764
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China
MAX-10181 Given Orally to Patients With Advanced Solid Tumor
- First Posted Date
- 2019-10-10
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- Maxinovel Pty., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT04122339
- Locations
- 🇦🇺
Linear Clinical Research, Nedlands, Western Australia, Australia
© Copyright 2025. All Rights Reserved by MedPath